Veeva Systems stock (US9224171002): Cloud solutions leader for life sciences

Veeva Systems delivers SaaS tools for pharma and biotech, supporting clinical trials, regulatory compliance and commercial operations amid digital transformation in healthcare.

Veeva Systems provides cloud-based software solutions tailored for the life sciences industry, including pharmaceuticals, biotechnology and contract research organizations. The company reported fiscal first-quarter 2026 results on May 1, 2026, with revenue of $905.9 million, up 26% year-over-year, according to Veeva IR as of 05/01/2026. This performance beat analyst expectations and underscores strong demand for its Veeva Vault platform.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Veeva Systems Inc
• Sector/industry: Software - life sciences SaaS
• Headquarters/country: Pleasanton, California, USA
• Core markets: North America, Europe, Asia-Pacific
• Key revenue drivers: Subscription services, professional services
• Home exchange/listing venue: NYSE (VEEV)
• Trading currency: USD

Veeva Systems: core business model

Veeva Systems operates a unified cloud platform designed specifically for life sciences companies. Its flagship Veeva Vault applications handle content management, quality compliance, clinical operations and commercial customer relationship management. Over 1,000 customers, including most of the top 20 pharma firms, rely on Veeva's solutions, as noted in the company's 10-K filing for fiscal 2025 as of 03/31/2025.

The subscription-based model generates recurring revenue, with professional services adding implementation and customization fees. Veeva's focus on industry-specific workflows differentiates it from general-purpose enterprise software providers.

Main revenue and product drivers for Veeva Systems

Subscription services accounted for 89% of total revenue in Q1 fiscal 2026, reaching $804.6 million, up 28% from the prior year, per the earnings release. Key products include Vault CRM, Vault Clinical and Vault Safety, which streamline regulatory submissions and trial management. Veeva Development Cloud saw 30% growth, driven by demand for electronic trial master files.

Professional services revenue grew 16% to $101.3 million. The company's expansion into commercial applications, like Veeva Commercial Cloud, supports sales and marketing digitization for biopharma clients.

Industry trends and competitive position

The life sciences software market is projected to grow at 12% CAGR through 2030, fueled by regulatory pressures and digitalization, according to Gartner as of 02/2026. Veeva holds a leading position with high customer retention rates above 95% and net retention of 120% in recent quarters.

Competitors include Oracle Health Sciences and IQVIA, but Veeva's single-instance, multi-tenant architecture offers scalability advantages for global compliance needs.

Why Veeva Systems matters for US investors

Listed on NYSE under VEEV, Veeva benefits from strong US pharma market exposure, where top customers like Pfizer and Merck drive over 50% of revenue. Its role in accelerating drug development amid US biotech funding cycles makes it relevant for investors tracking healthcare innovation.

Conclusion

Veeva Systems continues to execute on its growth strategy, with robust Q1 results highlighting demand for its specialized cloud platform. Ongoing investments in AI-driven features and international expansion position it amid evolving life sciences needs. Investors monitor upcoming fiscal guidance and sector dynamics for further insights.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.